Home › Trials › NCT05879757

Using HyQvia for treating adults with multiple myeloma and secondary immunodeficiency

A Prospective, Observational Study to Assess the Real-World Usage and Outcomes of HyQvia in Patients With Multiple Myeloma (MM) Diagnosed With Secondary Immunodeficiency (SID)

Observational Takeda · NCT05879757

This study is testing how well HyQvia works for adults with multiple myeloma and a weakened immune system by looking at their treatment experiences over a year.

Quick facts

Study typeObservational
Enrollment75 (estimated)
Ages18 Years and up
SexAll
SponsorTakeda Industry-sponsored
Drugs / interventionsCAR-T, chimeric antigen receptor
Locations27 sites (Córdoba and 26 other locations)
Trial IDNCT05879757 on ClinicalTrials.gov

What this trial studies

This observational study focuses on adults diagnosed with multiple myeloma who also have secondary immunodeficiency. Participants will receive HyQvia as part of their standard clinical care, and the study aims to gather data on the infusion parameters associated with its administration. Approximately 100 participants will be enrolled, and data will be collected during routine clinic visits over a period of 12 months. The study will take place across selected locations in Europe and South America.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with multiple myeloma and are starting HyQvia treatment as part of their routine care.

Not a fit: Patients who do not have multiple myeloma or secondary immunodeficiency, or those who are not starting HyQvia treatment within the specified timeframe, may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide insights into the effective use of HyQvia for managing multiple myeloma patients with secondary immunodeficiency.

How similar studies have performed: While this study is observational and focuses on real-world data, similar approaches in other studies have shown promise in understanding treatment parameters for various conditions.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

Participants who meet all of the following criteria assessed at the time of enrollment are eligible for this study:

1. Ability and willingness to provide informed consent. For adult participants unable to provide informed consent, informed consent provided by the legally authorized representative (LAR).
2. Has a diagnosis of MM requiring systemic anti-myeloma therapy as per International Myeloma Working Group (IMWG) criteria.
3. Initiated HyQvia treatment as part of routine clinical care no more than 30 days before study enrollment or received no more than 2 doses of HyQvia treatment, whichever occurs first. Participants are also eligible if they newly start HyQvia within 30 days after the enrollment visit.

   Note: Participants who do not start HyQvia treatment within 30 days of enrollment will be considered as screen failures (and replaced).
4. Age \>=18 years old at the time of MM diagnosis.
5. Available medical history records starting from the diagnosis of MM requiring systemic anti-myeloma therapy as IMWG criteria.
6. Life expectancy \>6 months at the time of enrollment, per physician assessment.
7. Eastern Cooperative Oncology Group (ECOG) performance status score of \<=2.
8. Participants/LAR willing and able to comply with the requirements of the protocol.

Exclusion Criteria:

Participants who meet any of the following criteria assessed at the time of enrollment are not eligible for this study:

1. Known hypersensitivity to any of the components of HyQvia.
2. Primary immunodeficiency (PID) or diagnosed with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) and/or active hepatitis C and/or active hepatitis B infection.
3. Prior use of Ig treatment or prophylaxis within 3 months from the date of enrollment.
4. Serious infection(s) requiring intravenous (IV) treatment at the time of enrollment into the study; except for participants on short-term oral antibiotic therapy.
5. Has participated in an interventional clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in an interventional clinical study involving a medical product or device during this study.

   Note: Participants on investigational chimeric antigen receptor-T (CAR-T) cell therapies and/or bispecific antibodies may participate.
6. Planned stem cell transplant during the treatment period or had a prior stem cell transplant: allogeneic transplant at any time, autologous transplant within 3 months of enrollment.
7. History of malignancy (other than MM) within 3 years before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix or breast, localized prostate cancer or other non-invasive lesion that in the opinion of the investigator, is considered cured with minimal risk of recurrence within 3 years).
8. Participant has had major surgery within 2 weeks before enrollment, or has not fully recovered from an earlier surgery, or has surgery planned during the time the participant is expected to participate in the study.

Note: Participants with planned surgical procedures to be conducted under local anesthesia may participate. Kyphoplasty or vertebroplasty are not considered major surgery.

Where this trial is running

Córdoba and 26 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Multiple MyelomaSecondary ImmunodeficiencyDrug TherapySupportive Therapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.